Centrix Pharma Solutions is stepping up its international growth ambitions with the appointment of pharmaceutical industry veteran Nathalie Huther as Senior Vice President of Business Development and Commercial.
Huther, who brings more than 20 years of experience across the life sciences and pharmaceutical sectors, will lead the UK-based Contract Development and Manufacturing Organisation’s (CDMO) commercial strategy, spearheading international expansion, strengthening customer partnerships and unlocking new business opportunities.
Her appointment marks a significant move as Centrix looks to build on its technical capabilities and strengthen its position as a specialist development and manufacturing partner to pharmaceutical and biotechnology companies.
Huther brings a strong track record of commercial leadership, having held senior positions at leading pharmaceutical services and technology businesses, including Arcinova, Nanoform, Quotient Sciences and Sai Life Sciences.
At Arcinova, she led the development and expansion of the EMEA business, delivering substantial revenue growth and strengthening the company's market position ahead of its acquisition by Quotient Sciences in 2021.
Most recently, as Chief Commercial Officer at independent UK CDMO High Force Research (HFR), she established and developed the company's commercial function, sharpened its market positioning and identified opportunities for international expansion.
Her industry credentials were also recognised by the UK Department for International Trade, which named her a Northern Powerhouse Export Champion in both 2020 and 2021.
At Centrix, Huther will focus on accelerating international business development, deepening strategic customer relationships and identifying new commercial opportunities. She will work closely with technical and operational teams to align customer needs with the company's expertise in formulation development, analytical services and GMP clinical manufacturing.
Commenting on her appointment, Huther said: "Centrix has strong technical expertise in drug product development and clinical manufacturing, with a specific ability to support companies with complex formulation and development challenges. I was attracted by the opportunity to build on these strengths and help realise the company’s commercial potential.
“There is a clear opportunity for specialist CDMOs that combine scientific expertise with flexibility and a collaborative approach. I’m looking forward to working with the team to strengthen our international presence, develop lasting customer partnerships, and help more innovative medicines progress towards clinical development.”
Chris Davison, CEO of Centrix Pharma Solutions, said the appointment comes at a pivotal stage in the company's development, following several years of investment in its drug product development and clinical manufacturing capabilities.
"Over the past few years, we’ve focused on building Centrix’s drug product development and clinical manufacturing capabilities. With ambitious plans for the business, now is the right time to strengthen our commercial leadership and build on those foundations.
“Nathalie brings a valuable combination of scientific understanding, international commercial experience and a proven track record of business growth. Importantly, she shares our approach to business development, which is about understanding our clients’ challenges, identifying where we can genuinely add value and building long-term relationships.
“Her appointment will help us sharpen our commercial focus, expand our international reach and engage with clients earlier in their development programmes, bringing together the right expertise from across Centrix and our wider partnerships. We’re delighted to welcome her to the team.”
